Download PDF
Digestive Disease Interventions 2020; 04(01): 003-012
DOI: 10.1055/s-0040-1702996
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Liver Transplantation for Locally Advanced Hepatocellular Carcinoma

Norio Kawamura
1   Department of Transplant Surgery, Hokkaido University Graduate School of Medicine, Hokkaido, Japan
,
Akinobu Taketomi
1   Department of Transplant Surgery, Hokkaido University Graduate School of Medicine, Hokkaido, Japan
2   Department of Gastroenterological Surgery 1, Hokkaido University Hospital, Hokkaido, Japan
› Author Affiliations
Further Information

Publication History

18 December 2019

06 January 2020

Publication Date:
06 March 2020 (online)

Also available at
    Permissions and Reprints

Abstract

Since the Milan criteria were accepted as the gold standard, liver transplantation has been widely performed as a curative treatment for early-stage hepatocellular carcinoma (HCC). The outcome of liver transplantation in early-stage HCC is excellent; however, the Milan criteria are strict, and therefore, only limited numbers of patients can benefit from liver transplantation. Many HCC patients are diagnosed at an advanced stage, which falls outside the Milan criteria, so it has been proposed over the last two decades that liver transplant surgeons should perform liver transplantation in locally advanced HCC, when presenting without recurrence. Several trials exploring the upper limits of liver transplantation have been performed, and extensive research on tumor biology has enabled the expansion of liver transplant indication for HCC. Simultaneously, locoregional therapy for advanced HCC was found to be an effective procedure when used to distinguish potentially transplantable patients. This treatment approach, known as a downstaging strategy, has been developed over the last two decades and became an essential treatment option for locally advanced HCC. In this article, the current strategies of liver transplantation for the treatment of locally advanced HCC are reviewed.

Keywords

hepatocellular carcinoma - liver transplantation - expanded criteria
 

  • References

  • 1 Fitzmaurice C, Akinyemiju TF, Al Lami FH. , et al; Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol 2018; 4 (11) 1553-1568
    CrossrefPubMedGoogle Scholar
  • 2 Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 2019; 16 (10) 589-604
    CrossrefPubMedGoogle Scholar
  • 3 Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64 (01) 73-84
    CrossrefPubMedGoogle Scholar
  • 4 Park JW, Chen M, Colombo M. , et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study. Liver Int 2015; 35 (09) 2155-2166
    CrossrefPubMedGoogle Scholar
  • 5 Yeh H, Smoot E, Schoenfeld DA, Markmann JF. Geographic inequity in access to livers for transplantation. Transplantation 2011; 91 (04) 479-486
    CrossrefPubMedGoogle Scholar
  • 6 Iwatsuki S, Starzl TE. Role of liver transplantation in the treatment of hepatocellular carcinoma. Semin Surg Oncol 1993; 9 (04) 337-340
    CrossrefPubMedGoogle Scholar
  • 7 Penn I. Hepatic transplantation for primary and metastatic cancers of the liver. Surgery 1991; 110 (04) 726-734 , discussion 734–735
    PubMedGoogle Scholar
  • 8 Mazzaferro V, Regalia E, Doci R. , et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334 (11) 693-699
    CrossrefPubMedGoogle Scholar
  • 9 Yao FY, Ferrell L, Bass NM. , et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33 (06) 1394-1403
    CrossrefPubMedGoogle Scholar
  • 10 Decaens T, Roudot-Thoraval F, Hadni-Bresson S. , et al. Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl 2006; 12 (12) 1761-1769
    CrossrefPubMedGoogle Scholar
  • 11 De Carlis L, Giacomoni A, Lauterio A. , et al. Liver transplantation for hepatocellular cancer: should the current indication criteria be changed?. Transpl Int 2003; 16 (02) 115-122
    CrossrefPubMedGoogle Scholar
  • 12 Iwatsuki S, Gordon RD, Shaw Jr BW, Starzl TE. Role of liver transplantation in cancer therapy. Ann Surg 1985; 202 (04) 401-407
    CrossrefPubMedGoogle Scholar
  • 13 Iwatsuki S, Starzl TE, Sheahan DG. , et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991; 214 (03) 221-228 , discussion 228–229
    CrossrefPubMedGoogle Scholar
  • 14 Jonas S, Bechstein WO, Steinmüller T. , et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33 (05) 1080-1086
    CrossrefPubMedGoogle Scholar
  • 15 Hayashi PH, Trotter JF, Forman L. , et al. Impact of pretransplant diagnosis of hepatocellular carcinoma on cadveric liver allocation in the era of MELD. Liver Transpl 2004; 10 (01) 42-48
    CrossrefPubMedGoogle Scholar
  • 16 Shah SA, Tan JC, McGilvray ID. , et al. Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma. Transplantation 2006; 81 (12) 1633-1639
    CrossrefPubMedGoogle Scholar
  • 17 Yoo HY, Patt CH, Geschwind JF, Thuluvath PJ. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol 2003; 21 (23) 4329-4335
    CrossrefPubMedGoogle Scholar
  • 18 Roayaie S, Llovet JM. Liver transplantation for hepatocellular carcinoma: is expansion of criteria justified?. Clin Liver Dis 2005; 9 (02) 315-328
    CrossrefPubMedGoogle Scholar
  • 19 Eng SC, Kowdley KV. Expansion of criteria for liver transplantation in HCC: a slippery slope?. Gastroenterology 2002; 122 (02) 579-582
    CrossrefPubMedGoogle Scholar
  • 20 Marsh JW, Dvorchik I. Liver organ allocation for hepatocellular carcinoma: are we sure?. Liver Transpl 2003; 9 (07) 693-696
    CrossrefPubMedGoogle Scholar
  • 21 Sugawara Y, Tamura S, Makuuchi M. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis 2007; 25 (04) 310-312
    CrossrefPubMedGoogle Scholar
  • 22 Toso C, Trotter J, Wei A. , et al. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2008; 14 (08) 1107-1115
    CrossrefPubMedGoogle Scholar
  • 23 Lee SG, Hwang S, Moon DB. , et al. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl 2008; 14 (07) 935-945
    CrossrefPubMedGoogle Scholar
  • 24 Mazzaferro V, Llovet JM, Miceli R. , et al; Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10 (01) 35-43
    CrossrefPubMedGoogle Scholar
  • 25 Shetty K, Timmins K, Brensinger C. , et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 2004; 10 (07) 911-918
    CrossrefPubMedGoogle Scholar
  • 26 Pawlik TM, Delman KA, Vauthey JN. , et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005; 11 (09) 1086-1092
    CrossrefPubMedGoogle Scholar
  • 27 Takada Y, Ito T, Ueda M. , et al. Living donor liver transplantation for patients with HCC exceeding the Milan criteria: a proposal of expanded criteria. Dig Dis 2007; 25 (04) 299-302
    CrossrefPubMedGoogle Scholar
  • 28 Zheng SS, Xu X, Wu J. , et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 2008; 85 (12) 1726-1732
    CrossrefPubMedGoogle Scholar
  • 29 Duvoux C, Roudot-Thoraval F, Decaens T. , et al; Liver Transplantation French Study Group. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012; 143 (04) 986-94.e3 , quiz e14–e15
    CrossrefPubMedGoogle Scholar
  • 30 Shimamura T, Akamatsu N, Fujiyoshi M. , et al; Japanese Liver Transplantation Society. Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: the 5-5-500 rule—a retrospective study. Transpl Int 2019; 32 (04) 356-368
    CrossrefPubMedGoogle Scholar
  • 31 Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. J Hepatol 1999; 31 (01) 133-141
    CrossrefPubMedGoogle Scholar
  • 32 Farinati F, Rinaldi M, Gianni S, Naccarato R. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer 2000; 89 (11) 2266-2273
    CrossrefPubMedGoogle Scholar
  • 33 Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology 2009; 49 (03) 832-838
    CrossrefPubMedGoogle Scholar
  • 34 Mazzaferro V, Sposito C, Zhou J. , et al. Metroticket 2.0 Model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterology 2018; 154 (01) 128-139
    CrossrefPubMedGoogle Scholar
  • 35 Sasaki K, Firl DJ, Hashimoto K. , et al. Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis. Lancet Gastroenterol Hepatol 2017; 2 (08) 595-603
    CrossrefPubMedGoogle Scholar
  • 36 Huo TI, Lin HC, Hsia CY. , et al. The MELD-Na is an independent short- and long-term prognostic predictor for hepatocellular carcinoma: a prospective survey. Dig Liver Dis 2008; 40 (11) 882-889
    CrossrefPubMedGoogle Scholar
  • 37 Hsu CY, Huang YH, Hsia CY. , et al. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei integrated scoring system. J Hepatol 2010; 53 (01) 108-117
    CrossrefPubMedGoogle Scholar
  • 38 Firl DJ, Sasaki K, Agopian VG. , et al; European Hepatocellular Cancer Liver Transplant Study Group. Charting the path forward for risk prediction in liver transplant for hepatocellular carcinoma: international validation of HALTHCC among 4,089 patients. Hepatology 2019 (e-pub ahead of print). Doi: 10.1002/hep.30838
    PubMedGoogle Scholar
  • 39 Pomfret EA, Washburn K, Wald C. , et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010; 16 (03) 262-278
    CrossrefPubMedGoogle Scholar
  • 40 Majno PE, Adam R, Bismuth H. , et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997; 226 (06) 688-701 , discussion 701–703
    CrossrefPubMedGoogle Scholar
  • 41 Yao FY, Hirose R, LaBerge JM. , et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl 2005; 11 (12) 1505-1514
    CrossrefPubMedGoogle Scholar
  • 42 Ravaioli M, Grazi GL, Piscaglia F. , et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 2008; 8 (12) 2547-2557
    CrossrefPubMedGoogle Scholar
  • 43 Chapman WC, Majella Doyle MB, Stuart JE. , et al. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg 2008; 248 (04) 617-625
    CrossrefPubMedGoogle Scholar
  • 44 Lewandowski RJ, Kulik LM, Riaz A. , et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009; 9 (08) 1920-1928
    CrossrefPubMedGoogle Scholar
  • 45 De Luna W, Sze DY, Ahmed A. , et al. Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation. Am J Transplant 2009; 9 (05) 1158-1168
    CrossrefPubMedGoogle Scholar
  • 46 Jang JW, You CR, Kim CW. , et al. Benefit of downsizing hepatocellular carcinoma in a liver transplant population. Aliment Pharmacol Ther 2010; 31 (03) 415-423
    CrossrefPubMedGoogle Scholar
  • 47 Barakat O, Wood RP, Ozaki CF. , et al. Morphological features of advanced hepatocellular carcinoma as a predictor of downstaging and liver transplantation: an intention-to-treat analysis. Liver Transpl 2010; 16 (03) 289-299
    CrossrefPubMedGoogle Scholar
  • 48 Green TJ, Rochon PJ, Chang S. , et al. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization. J Vasc Interv Radiol 2013; 24 (11) 1613-1622
    CrossrefPubMedGoogle Scholar
  • 49 Otto G, Herber S, Heise M. , et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006; 12 (08) 1260-1267
    CrossrefPubMedGoogle Scholar
  • 50 Millonig G, Graziadei IW, Freund MC. , et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2007; 13 (02) 272-279
    CrossrefPubMedGoogle Scholar
  • 51 Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A. ; OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13 (01) e11-e22
    CrossrefPubMedGoogle Scholar
  • 52 Bryce K, Tsochatzis EA. Downstaging for hepatocellular cancer: harm or benefit?. Transl Gastroenterol Hepatol 2017; 2: 106
    CrossrefPubMedGoogle Scholar
  • 53 Yao FY. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant 2008; 8 (10) 1982-1989
    CrossrefPubMedGoogle Scholar
  • 54 Yao FY, Mehta N, Flemming J. , et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology 2015; 61 (06) 1968-1977
    CrossrefPubMedGoogle Scholar
  • 55 Ravaioli M, Odaldi F, Cucchetti A. , et al. Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria. Sci Rep 2019; 9 (01) 3781
    CrossrefPubMedGoogle Scholar
  • 56 Sinha J, Mehta N, Dodge JL, Poltavskiy E, Roberts J, Yao F. Are there upper limits in tumor burden for down-staging of hepatocellular carcinoma to liver transplant? Analysis of the all-comers protocol. Hepatology 2019; 70 (04) 1185-1196
    CrossrefPubMedGoogle Scholar
  • 57 Mehta N, Guy J, Frenette CT. , et al. Excellent outcomes of liver transplantation following down-staging of hepatocellular carcinoma to within Milan Criteria: a multicenter study. Clin Gastroenterol Hepatol 2018; 16 (06) 955-964
    CrossrefPubMedGoogle Scholar
  • 58 Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007; 7 (11) 2587-2596
    CrossrefPubMedGoogle Scholar
  • 59 Lencioni R, Montal R, Torres F. , et al. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. J Hepatol 2017; 66 (06) 1166-1172
    CrossrefPubMedGoogle Scholar
  • 60 Na GH, Kim EY, Hong TH, You YK, Kim DG. Effects of loco regional treatments before living donor liver transplantation on overall survival and recurrence-free survival in South Korean patients with hepatocellular carcinoma. HPB (Oxford) 2016; 18 (01) 98-106
    CrossrefPubMedGoogle Scholar
  • 61 Garwood ER, Fidelman N, Hoch SE, Kerlan Jr RK, Yao FY. Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction. Liver Transpl 2013; 19 (02) 164-173
    CrossrefPubMedGoogle Scholar
  • 62 Lai Q, Nudo F, Mennini G. , et al. Expanded criteria for hepatocellular carcinoma after liver transplantation: a 20-year evolution. Hepatogastroenterology 2013; 60 (128) 2039-2041
    PubMedGoogle Scholar
  • 63 Bruix J, Raoul JL, Sherman M. , et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 2012; 57 (04) 821-829
    CrossrefPubMedGoogle Scholar
  • 64 Llovet JM, Ricci S, Mazzaferro V. , et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359 (04) 378-390
    CrossrefPubMedGoogle Scholar
  • 65 Edeline J, Crouzet L, Campillo-Gimenez B. , et al. Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis. Eur J Nucl Med Mol Imaging 2016; 43 (04) 635-643
    CrossrefPubMedGoogle Scholar
  • 66 Levi Sandri GB, Ettorre GM, Colasanti M. , et al. Hepatocellular carcinoma with macrovascular invasion treated with yttrium-90 radioembolization prior to transplantation. Hepatobiliary Surg Nutr 2017; 6 (01) 44-48
    CrossrefPubMedGoogle Scholar
  • 67 Dendy MS, Camacho JC, Ludwig JM, Krasinskas AM, Knechtle SJ, Kim HS. Infiltrative hepatocellular carcinoma with portal vein tumor thrombosis treated with a single high-dose Y90 radioembolization and subsequent liver transplantation without a recurrence. Transplant Direct 2017; 3 (09) e206
    PubMedGoogle Scholar
  • 68 Siegler M, Simmerling MC, Siegler JH, Cronin II DC. Recipient deaths during donor surgery: a new ethical problem in living donor liver transplantation (LDLT). Liver Transpl 2006; 12 (03) 358-360
    CrossrefPubMedGoogle Scholar
  • 69 Kaido T, Ogawa K, Mori A. , et al. Usefulness of the Kyoto criteria as expanded selection criteria for liver transplantation for hepatocellular carcinoma. Surgery 2013; 154 (05) 1053-1060
    CrossrefPubMedGoogle Scholar
  • 70 Akamatsu N, Sugawara Y, Kokudo N. Living donor liver transplantation for patients with hepatocellular carcinoma. Liver Cancer 2014; 3 (02) 108-118
    CrossrefPubMedGoogle Scholar
  • 71 Shirabe K, Itoh S, Yoshizumi T. , et al. The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin. J Surg Oncol 2007; 95 (03) 235-240
    CrossrefPubMedGoogle Scholar
  • 72 Fujiki M, Takada Y, Ogura Y. , et al. Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma. Am J Transplant 2009; 9 (10) 2362-2371
    CrossrefPubMedGoogle Scholar
  • 73 Taketomi A, Sanefuji K, Soejima Y. , et al. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation 2009; 87 (04) 531-537
    CrossrefPubMedGoogle Scholar
  • 74 Takada Y, Kaido T, Shirabe K. , et al; LTx-PET study group of the Japanese Society of Hepato-Biliary-Pancreatic Surgery and the Japanese Liver Transplantation Society. Significance of preoperative fluorodeoxyglucose-positron emission tomography in prediction of tumor recurrence after liver transplantation for hepatocellular carcinoma patients: a Japanese multicenter study. J Hepatobiliary Pancreat Sci 2017; 24 (01) 49-57
    CrossrefPubMedGoogle Scholar
  • 75 Kulik LM, Fisher RA, Rodrigo DR. , et al; A2ALL Study Group. Outcomes of living and deceased donor liver transplant recipients with hepatocellular carcinoma: results of the A2ALL cohort. Am J Transplant 2012; 12 (11) 2997-3007
    CrossrefPubMedGoogle Scholar
  • 76 Vakili K, Pomposelli JJ, Cheah YL. , et al. Living donor liver transplantation for hepatocellular carcinoma: increased recurrence but improved survival. Liver Transpl 2009; 15 (12) 1861-1866
    CrossrefPubMedGoogle Scholar
  • 77 Goldaracena N, Gorgen A, Doyle A. , et al. Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation. J Hepatol 2019; 70 (04) 666-673
    CrossrefPubMedGoogle Scholar
  • 78 Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol 2017; 14 (04) 203-217
    PubMedGoogle Scholar
  • 79 Schaubel DE, Guidinger MK, Biggins SW. , et al. Survival benefit-based deceased-donor liver allocation. Am J Transplant 2009; 9 (4 Pt 2): 970-981
    CrossrefPubMedGoogle Scholar
  • 80 Vitale A, Morales RR, Zanus G. , et al; Italian Liver Cancer group. Barcelona clinic liver cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. Lancet Oncol 2011; 12 (07) 654-662
    CrossrefPubMedGoogle Scholar
  • 81 Quaglia A, Etessami N, Sim R, Difford J, Dhillon AP. Vascular invasion and herniation by hepatocellular carcinoma in cirrhosis: a wolf in sheep's clothing?. Arch Pathol Lab Med 2005; 129 (05) 639-644
    CrossrefPubMedGoogle Scholar
  • 82 Hojo M, Morimoto T, Maluccio M. , et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397 (6719): 530-534
    CrossrefPubMedGoogle Scholar
  • 83 Rodríguez-Perálvarez M, Tsochatzis E, Naveas MC. , et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol 2013; 59 (06) 1193-1199
    CrossrefPubMedGoogle Scholar
  • 84 Vivarelli M, Cucchetti A, La Barba G. , et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg 2008; 248 (05) 857-862
    CrossrefPubMedGoogle Scholar
  • 85 Vivarelli M, Cucchetti A, Piscaglia F. , et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl 2005; 11 (05) 497-503
    CrossrefPubMedGoogle Scholar
  • 86 Decaens T, Roudot-Thoraval F, Bresson-Hadni S. , et al. Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. World J Gastroenterol 2006; 12 (45) 7319-7325
    CrossrefPubMedGoogle Scholar
  • 87 Xu X, Ye L, Araki K, Ahmed R. mTOR, linking metabolism and immunity. Semin Immunol 2012; 24 (06) 429-435
    CrossrefPubMedGoogle Scholar
  • 88 Sieghart W, Fuereder T, Schmid K. , et al. Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation 2007; 83 (04) 425-432
    CrossrefPubMedGoogle Scholar
  • 89 Zimmerman MA, Trotter JF, Wachs M. , et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 2008; 14 (05) 633-638
    CrossrefPubMedGoogle Scholar
  • 90 Chinnakotla S, Davis GL, Vasani S. , et al. Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl 2009; 15 (12) 1834-1842
    CrossrefPubMedGoogle Scholar
  • 91 Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010; 51 (04) 1237-1243
    CrossrefPubMedGoogle Scholar
  • 92 Geissler EK, Schnitzbauer AA, Zülke C. , et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial. Transplantation 2016; 100 (01) 116-125
    CrossrefPubMedGoogle Scholar
  • 93 Rodríguez-Perálvarez M, Guerrero M, Barrera L. , et al. Impact of early initiated everolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Transplantation 2018; 102 (12) 2056-2064
    CrossrefPubMedGoogle Scholar
  • 94 Satapathy SK, Das K, Kocak M. , et al. No apparent benefit of preemptive sorafenib therapy in liver transplant recipients with advanced hepatocellular carcinoma on explant. Clin Transplant 2018; 32 (05) e13246
    CrossrefPubMedGoogle Scholar
  • 95 Shetty K, Dash C, Laurin J. Use of adjuvant sorafenib in liver transplant recipients with high-risk hepatocellular carcinoma. J Transplant 2014; 2014: 913634
    PubMedGoogle Scholar
  • 96 Saab S, McTigue M, Finn RS, Busuttil RW. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy. Exp Clin Transplant 2010; 8 (04) 307-313
    PubMedGoogle Scholar
  • 97 Chen ZN, Mi L, Xu J. , et al. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials. Int J Radiat Oncol Biol Phys 2006; 65 (02) 435-444
    CrossrefPubMedGoogle Scholar
  • 98 Xu J, Shen ZY, Chen XG. , et al. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology 2007; 45 (02) 269-276
    CrossrefPubMedGoogle Scholar
  • 99 DeLeon TT, Salomao MA, Aqel BA. , et al. Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience. J Gastrointest Oncol 2018; 9 (06) 1054-1062
    CrossrefPubMedGoogle Scholar
  • 100 Graziadei IW, Sandmueller H, Waldenberger P. , et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impeded tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003; 9 (06) 557-563
    CrossrefPubMedGoogle Scholar